Centrifuge the vial (10,000 x g for 5 minutes) before adding solvent to spin down all the powder to the bottom of the vial. The lyophilized product may be difficult to visualize. Add solvent directly to the centrifuged vial. Gently tap, tilt, and roll the vial to aid dissolution. Avoid vigorous vortexing, light vortexing for up to 3 seconds is acceptable if needed. The product is soluble in pure water at high micromolar concentrations (100 μM - 1 mM). For long-term storage in solution, we recommend preparing a stock solution by dissolving the product in double-distilled water (ddH2O) at a concentration between 100-1000x of the final working concentration. Divide the stock solution into small aliquots and store at -20 °C. Before use, thaw the relevant vial(s) and dilute to the desired working concentration in your working buffer. Centrifuge all product preparations before use. It is recommended to prepare fresh solutions in working buffers just before use. Avoid multiple freeze-thaw cycles to maintain biological activity.
Buffer
Lyophilized from double distilled water (ddH2O). May contain TFA as a residual counter ion.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
The reconstituted solution can be stored at 4°C for up to 1 week. For longer periods (up to 6 months), small aliquots should be stored at -20°C. We do not recommend storing the product in working solutions for longer than a few days. Avoid multiple freeze-thaw cycles.,The reconstituted solution can be stored at 4°C for up to 1 week. For longer periods (up to 6 months), small aliquots should be stored at -20°C. We do not recommend storing the product in working solutions for longer than a few days. Avoid multiple freeze-thaw cycles.
Target
Mast Cell-Degranulating Peptide (MCDP)
Hintergrund
Mast cell degranulating peptide, MCDP, Peptide 401,MCD peptide (Mast Cell Degranulating Peptide) is a 22 amino acid peptidyl toxin isolated from Apis mellifera bee venom1. MCD peptide induces histamine release from mast cells2 and release of glutamate in CA1 region of rat hippocampus in dose-dependent manner3.MCD peptide was shown to block KV1.2 channels in Xenopus oocytes4 and to inhibit KV1.1 (IC50 490 nM) and KV1.2 (IC50 440 nM) expressed in cell lines while having no effect on KV1.3, KV1.5 and KV3.15. In accordance, MCD peptide (6.4 μM) enhances the magnitude of field potentials in CA1 region as recorded in hippocampal slices6 and induces epileptiform seizures and brain damage after intracerebroventricular injection of 200 pM in rats7.